3-Acetoxy-α,α,α-trifluor-p-toluylsure
|
|
|
- CAS-Nr.
- 322-79-2
- Bezeichnung:
- 3-Acetoxy-α,α,α-trifluor-p-toluylsure
- Englisch Name:
- Triflusal
- Synonyma:
- ur1501;Drisgen;Disgren;TRIFLUSAL;Triflusal-d3;Triflusal CRS;Triflusal (UR1501);TRIFLUOROTRIMESICACID;4-trifluoromethylsalicylicacidacetate;acetyl-4-trifluoromethylsalicylic acid
- CBNumber:
- CB9446472
- Summenformel:
- C10H7F3O4
- Molgewicht:
- 248.16
- MOL-Datei:
- 322-79-2.mol
|
3-Acetoxy-α,α,α-trifluor-p-toluylsure Eigenschaften
- Schmelzpunkt:
- 120-122° (upon slow heating); 110-112° (upon quick heating)
- Siedepunkt:
- 316.0±42.0 °C(Predicted)
- Dichte
- 1.433±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,2-8°C
- L?slichkeit
- DMSO: >30mg/mL
- pka
- 2.97±0.10(Predicted)
- Aggregatzustand
- powder
- Farbe
- white to off-white
- maximale Wellenl?nge (λmax)
- 297nm(H2O)(lit.)
- Merck
- 14,9688
- CAS Datenbank
- 322-79-2(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Kennzeichnung gef?hrlicher |
Xn |
|
|
| R-S?tze: |
22-36/37/38-43 |
|
|
| S-S?tze: |
26-36/37 |
|
|
| WGK Germany |
3 |
|
|
| RTECS-Nr. |
GP4250000 |
|
|
| HS Code |
2918.29.7500 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P333+P313 |
Bei Hautreizung oder -ausschlag: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
3-Acetoxy-α,α,α-trifluor-p-toluylsure Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
White to Off-White Solid
Verwenden
An analog of Aspirin; inhibits platelet aggregation. Antithrombotic.
Mechanism of action
2-hydroxy-4-trifluoromethylbenzoic acid (HTB), the deacetylated
metabolite of triflusal, retains significant antiplatelet activity. Triflusal is rapidly absorbed and
metabolized. The area under the concentration–time curve for triflusal is 20.26 mg/L/hour after a
900-mg dose, whereas that for HTB is 42.27 mg/L/hour. Much of the pharmacokinetic data for
triflusal activity is associated with HTB. The inhibition of COX, as measured by reduced production
of thromboxane B2, is 25% after 2 hours and 85% after 7 days with triflusal, whereas the effects of
aspirin on thromboxane B2 is more than 90% reduction after 2 hours and is maintained at this level
after 7 days. It would appear that the presence of a 4-trifluoromethyl group also greatly enhances triflusal's ability to inhibit the activation of nuclear factor κB, which in turn regulates the
expression of the mRNA of vascular
cell adhesion molecule-1 needed for platelet aggregation. In addition, triflusal increases nitric
oxide synthesis in neutrophils, which results in an increased vasodilatory potential. Finally, an
additional site of action for triflusal/HTB is the inhibition of cAMP phosphodiesterase, leading to
increased levels of cAMP. Elevated cAMP levels decrease platelet aggregation through decreased
mobilization of calcium. Aspirin and salicylic acid do not significantly increase cAMP levels.
Clinical Use
Triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) is an antiplatelet drug that despite its structural
similarity to aspirin exhibits quite different pharmacological and pharmacokinetic
properties.
3-Acetoxy-α,α,α-trifluor-p-toluylsure Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
3-Acetoxy-α,α,α-trifluor-p-toluylsure Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 195)Lieferanten
322-79-2(3-Acetoxy-α,α,α-trifluor-p-toluylsure)Verwandte Suche:
Fluorsulfons?ure
Trifluormethansulfonsaeure
(Z)-(2-(4-(1,2-Diphenylbut-1-enyl)phenoxy)dimethylammonium-dihydrogen-2-hydroxypropan-1,2,3-tricarboxylat
Bis[(tert-butyl)(β,3,4-trihydroxyphenethyl)ammonium]sulfat
3-(10,11-Dihydro-5H-dibenzo(a,d)-cyclohepten-5-yliden)-N,N-dime-thyl-1-propanamin-hydrochlorid
p-Toluyls?ure
Benzoesure
α,α,α-Trifluor-p-toluylsure
2-Hydroxy-p-toluylsure
2-(Acetyloxy)benzoes?ure
3-Acetoxy-α,α,α-trifluor-p-toluylsure
- 2-acetoxy-4-trifluoromethylbenzoic acid
- 3-acetoxy-alpha,alpha,alpha-trifluoro-p-toluic acid
- 4-cresoticacid,alpha,alpha,alpha-trifluoro-acetate
- 4-trifluoromethylsalicylicacidacetate
- alpha,alpha,alpha-trifluoro-2,4-creosoticacidacetate
- ur1501
- 4-CRESOTIC ACID, ALPHA,ALPHA,ALPHA-TRIFLUORO- ACETATE, 99+%
- TRIFLUOROTRIMESICACID
- Disgren
- acetyl-4-trifluoromethylsalicylic acid
- Drisgen
- α,α,α-trifluoro-2,4-cresotic acid acetate
- Triflusal-d3
- Benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)-
- TRIFLUSAL
- 2-(acetyloxy)-4-(trifluoromethyl)-benzoicaci
- 2-(acetyloxy)-4-(trifluoromethyl)benzoicacid
- Triflusal CRS
- 2-Acetoxy-4-trifluoromethylbenzoic acid USP/EP/BP
- Triflusal (UR1501)
- 322-79-2
- C10H7F3O4
- Aromatics
- Drug Analogues
- Intermediates & Fine Chemicals
- Pharmaceuticals
- I
- APIs
